---
layout: default
title: Dexmedetomidine Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 170
evidence_level: L5
indication_count: 0
---

# Dexmedetomidine Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Dexmedetomidine Hydrochloride: Drug Repurposing Evaluation Report

## One-Sentence Summary

Dexmedetomidine hydrochloride is a marketed sedative agent currently registered in Malaysia with 10 licences. The TxGNN model did not return any predicted new indications for this drug, and critical data gaps (mechanism of action, approved indication text, safety data) remain unresolved. **No repurposing candidates can be evaluated at this time.**

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | *(Licence indication text not available in evidence pack)* |
| Predicted New Indication | **None** — no predictions returned by TxGNN |
| TxGNN Prediction Score | N/A |
| Evidence Level | **L5** (No predictions, no supporting studies) |
| Malaysia Market Status | ✓ Marketed (已上市) |
| Number of Registrations | 10 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on publicly known information, dexmedetomidine hydrochloride is a highly selective **alpha-2 adrenergic receptor agonist** primarily used for sedation in intensive care unit (ICU) settings and procedural sedation. It provides sedation, anxiolysis, and analgesia without significant respiratory depression.

However, the TxGNN model returned **no predicted new indications** for this drug. This may be due to one or more of the following reasons:

1. **Missing DrugBank ID mapping** — the evidence pack shows `drugbank_id: null`, which means the drug could not be mapped into the TxGNN knowledge graph. Without a valid node in the graph, no link predictions can be generated.
2. **Incomplete input data** — the original indications array is empty, and approved indication text was not retrieved from the regulatory database, limiting the model's ability to establish baseline disease-drug relationships.

Before any repurposing evaluation can proceed, the DrugBank mapping (expected: **DB00633**) and regulatory indication data must be resolved.

---

## Clinical Trial Evidence

Currently no related clinical trials are available in the evidence pack, as no new indication was predicted.

---

## Literature Evidence

Currently no related literature is available in the evidence pack, as no new indication was predicted.

---

## Malaysia Market Information

The evidence pack records **10 registered licences** for dexmedetomidine hydrochloride in Malaysia, but the licence detail fields (authorization number, product name, dosage form, approved indication) were not populated in the data extraction.

| Item | Content |
|------|------|
| Total Registrations | 10 |
| Market Status | Marketed (已上市) |
| Licence Details | Not available — data extraction returned empty fields |

> **Remediation**: Re-query the NPRA database to retrieve full licence details including authorization numbers, product names, dosage forms, and approved indication text.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note**: Key warnings, contraindications, and drug interaction data were not available in the evidence pack. The data gap assessment classifies the missing TFDA label warnings/contraindications as **Blocking** severity — this must be resolved before any safety evaluation (S1 stage) can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No new indications were predicted by TxGNN, likely due to the missing DrugBank ID mapping (`drugbank_id: null`) which prevents the drug from being located in the knowledge graph. Additionally, all core data fields (approved indications, MOA, safety information) are empty or flagged as data gaps.

**To proceed, the following is needed:**

1. **Resolve DrugBank mapping** — Query DrugBank for "dexmedetomidine" (expected ID: **DB00633**) and re-run the TxGNN prediction pipeline with the correct node mapping
2. **Retrieve NPRA licence details** — Re-extract the 10 registered licences with full fields (authorization number, product name, dosage form, approved indication text)
3. **Obtain mechanism of action data** — Retrieve MOA from DrugBank (alpha-2 adrenergic receptor agonist) to enable mechanistic plausibility analysis
4. **Obtain safety data** — Download and parse the package insert to extract key warnings, contraindications, and drug-drug interactions (classified as **Blocking** data gap)
5. **Re-run evidence pack generation** — After resolving the above gaps, regenerate the evidence pack and re-evaluate

---

*This report is for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

